A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005366

Enrollment

Unknown

Registered

2014-01-10

Start date

2014-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical membranous nephropathy

Interventions

Low-dose hormone plus cyclophosphamide (CTX) grou:hormone, cyclophosphamide, three months

hormone+CsA:hormone+CsA, three months

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Intends to select 40 cases of nephrotic syndrome, aged 18-70 years old, in Nephrology department in China-Japan Friendship Hospital between September 2014 to March 2015. Two groups, and each group has 20 cases. All the patients are nephrotic syndrome (which diagnostic criteria is 24 hours urinary protein more than 3.5g/d, serum albumin less than 30g/L), however, the serum creatinine less than 132.6umol/L (1.5mg/dl), and confirmed atypical membranous nephropathy by renal biopsy. The patients are Initial treatment, and there are not statistically significant difference in age and gender(P more than 0.05) and both are comparable.

Exclusion criteria

Exclusion criteria: 1. seropositive hepatitis B and hepatitis C virus associated glomerulonephritis (HBV DNA and HCV RNA viral replication prompt), lupus nephritis, thyroid and other parts of the tumor, organic solvents, heavy metal poisoning, such as the film clearly secondary to secondary causes nephropathy; 2. serious infection or central nervous system symptoms; 3. abnormal liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than two times the upper limit of normal; 4. cardiac insufficiency; 5. abnormal glucose metabolism: fasting glucose more than 6.1 mmol/L or postprandial blood glucose more than 7.8 mmol/L; 6. pregnant or lactating women; 7. white blood cell count more than 3.0*10^9/L, platelet count less than 50*10^9/L; 8. The patients have mental illness and poor compliance.

Design outcomes

Primary

Measure	Time frame
24-h protein excretion;	—

Secondary

Measure	Time frame
urinalysis;Blood analysis;blood urea nitrogen;serum creatinine;ALT;AST;	—

Contacts

Public ContactWenge Li

wenge_lee2002@126.com+86 13521961922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026